Opening avenues for treatment of neurodegenerative disease using post-biotics: Breakthroughs and bottlenecks in clinical translation
Bushra Bashir,Shahbaz Alam,Nikhil Khandale,Devendra Birla,Sukriti Vishwas,Narendra Kumar Pandey,Gaurav Gupta,Keshav Raj Paudel,Harish Dureja,Puneet Kumar,Thakur Gurjeet Singh,Gowthamarajan Kuppusamy,Flavia Zacconi,Terezinha de Jesus Andreoli Pinto,Muralikrishnan Dhanasekaran,Monica Gulati,Kamal Dua,Sachin Kumar Singh
DOI: https://doi.org/10.1016/j.arr.2024.102236
IF: 11.788
2024-02-19
Ageing Research Reviews
Abstract:Recent studies have indicated the significant involvement of the gut microbiome in both human physiology and pathology. Additionally, therapeutic interventions based on microbiome approaches have been employed to enhance overall health and address various diseases including aging and neurodegenerative disease (ND). Researchers have explored potential links between these areas, investigating the potential pathogenic or therapeutic effects of intestinal microbiota in diseases. This article provides a summary of established interactions between the gut microbiome and ND. Post-biotic is believed to mediate its neuroprotection by elevating the level of dopamine and reducing the level of α-synuclein in substantia nigra, protecting the loss of dopaminergic neurons, reducing the aggregation of NFT, reducing the deposition of amyloid β peptide plagues and ameliorating motor deficits. Moreover, mediates its neuroprotective activity by inhibiting the inflammatory response (decreasing the expression of TNFα, iNOS expression, free radical formation, overexpression of HIF-1α), apoptosis (i.e. active caspase-3, TNF-α, maintains the level of Bax/Bcl-2 ratio) and promoting BDNF secretion. It is also reported to have good antioxidant activity. This review offers an overview of the latest findings from both preclinical and clinical trials concerning the use of post-biotics in ND.
cell biology,geriatrics & gerontology,gerontology